Isomorphic Labs

Isomorphic Labs was founded in 2021 as a spinout from DeepMind, with a clear mission: use artificial intelligence to reinvent the way drugs are discovered. The company operates at the intersection of biology, computational chemistry, and machine learning, leveraging advanced architectures to model proteins, predict molecular interactions, and identify therapeutic candidates with a speed and precision unimaginable with traditional methods. The technological starting point is AlphaFold — the protein structure prediction system developed by DeepMind that revolutionised structural biology — but Isomorphic Labs goes well beyond: it approaches drug design as a computational optimisation problem, seeking to engineer molecules with desired pharmacological properties from the earliest development stage. In May 2026, the company closed a $2.1 billion Series B led by Thrive Capital, with participation from Alphabet, GV, CapitalG, Temasek, MGX, and the UK Sovereign AI Fund. This is one of the largest rounds ever seen in AI drug discovery and in European venture history, signalling entry into an industrial phase: no longer proof of concept, but real pipelines, clinical trials, and ambitions for global scale. Isomorphic Labs already collaborates with some of the world's leading pharma companies and aims to build a computational infrastructure for next-generation medicine, where every drug candidate is designed, optimised, and selected by AI before it ever enters a laboratory.